Oncology Nursing News explored the promise and limitations of circulating tumor DNA (ctDNA) testing for early-stage breast cancer. Dr. Sucharu Prakash, Medical Director of Quality Services for Texas Oncology, discussed the importance of allowing evidence to mature before widespread adoption, emphasizing that ctDNA testing for early-stage disease is best pursued within clinical trials while research continues.
